IMMUNITYBIO, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
IMMUNITYBIO, INC. (IBRX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $8.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- IMMUNITYBIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $8.52M, a 11.71% decline year-over-year.
- IMMUNITYBIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $8.17M, a 14.34% decline year-over-year.
- IMMUNITYBIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $8.88M, a 18.55% increase year-over-year.
- IMMUNITYBIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $9.65M, a 0.09% increase year-over-year.
- IMMUNITYBIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $36.81M, a 6.90% increase from fiscal 2024.
- IMMUNITYBIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $34.43M, a 29.96% decline from fiscal 2023.
- IMMUNITYBIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $49.16M, a 22.36% increase from fiscal 2022.
- IMMUNITYBIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $40.18M, a 29.73% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.52M 10-Q · filed 2026-08-04 | $16.69M derived: sum of 2 quarters · filed 2026-08-04 | ||||||
| 2026-03-31 | $8.17M 10-Q · filed 2026-08-04 | |||||||
| 2025-12-31 | $36.81M 10-K · filed 2026-02-23 | |||||||
| 2025-09-30 | $8.88M 10-Q · filed 2025-11-05 | $18.53M derived: sum of 2 quarters · filed 2026-08-04 | $28.06M derived: sum of 3 quarters · filed 2026-08-04 | |||||
| 2025-06-30 | $9.65M 10-Q · filed 2026-08-04 | $19.18M derived: sum of 2 quarters · filed 2026-08-04 | ||||||
| 2025-03-31 | $9.54M 10-Q · filed 2026-08-04 | |||||||
| 2024-12-31 | $34.43M 10-K · filed 2026-02-23 | |||||||
| 2024-09-30 | $7.49M 10-Q · filed 2025-11-05 | $17.13M derived: sum of 2 quarters · filed 2025-11-05 | $25.39M derived: sum of 3 quarters · filed 2025-11-05 | |||||
| 2024-06-30 | $9.64M 10-Q · filed 2025-11-05 | $17.91M derived: sum of 2 quarters · filed 2025-11-05 | ||||||
| 2024-03-31 | $8.27M 10-Q · filed 2025-11-05 | |||||||
| 2023-12-31 | $49.16M 10-K · filed 2026-02-23 | |||||||
| 2023-09-30 | $14.45M 10-Q · filed 2024-11-12 | $25.51M derived: sum of 2 quarters · filed 2024-11-12 | $36.39M derived: sum of 3 quarters · filed 2024-11-12 | |||||
| 2023-06-30 | $11.06M 10-Q · filed 2024-11-12 | $21.94M derived: sum of 2 quarters · filed 2024-11-12 | ||||||
| 2023-03-31 | $10.88M 10-Q · filed 2024-11-12 | |||||||
| 2022-12-31 | $40.18M 10-K · filed 2025-03-03 | |||||||
| 2022-09-30 | $10.63M 10-Q · filed 2023-11-09 | $20.80M derived: sum of 2 quarters · filed 2023-11-09 | $30.83M derived: sum of 3 quarters · filed 2023-11-09 | $41.01M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-06-30 | $10.18M 10-Q · filed 2023-11-09 | $20.20M 10-Q · filed 2022-08-08 | $30.38M derived: sum of 3 quarters · filed 2024-03-19 | $44.22M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-03-31 | $10.02M 10-Q · filed 2023-11-09 | $20.20M derived: sum of 2 quarters · filed 2024-03-19 | $34.04M derived: sum of 3 quarters · filed 2024-03-19 | $51.91M derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2021-12-31 | $10.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $24.02M derived: sum of 2 quarters · filed 2024-03-19 | $41.88M derived: sum of 3 quarters · filed 2024-03-19 | $57.18M 10-K · filed 2024-03-19 | ||||
| 2021-09-30 | $13.84M 10-Q · filed 2022-11-09 | $31.70M derived: sum of 2 quarters · filed 2022-11-09 | $47.00M 10-Q · filed 2021-11-12 | $47.67M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $17.86M 10-Q · filed 2022-11-09 | $33.16M 10-Q · filed 2022-08-08 | $33.83M derived: sum of 3 quarters · filed 2023-03-01 | $34.55M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $15.30M 10-Q · filed 2022-11-09 | $15.97M derived: sum of 2 quarters · filed 2023-03-01 | $16.68M derived: sum of 3 quarters · filed 2023-03-01 | $17.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | $671.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.39M derived: sum of 2 quarters · filed 2023-03-01 | $1.71M derived: sum of 3 quarters · filed 2023-03-01 | $2.19M 10-K · filed 2023-03-01 | $2.14M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $714.00K 10-Q · filed 2021-11-12 | $711.00K 10-Q · filed 2020-11-09 | $1.04M derived: sum of 2 quarters · filed 2021-11-12 | $1.52M 10-Q · filed 2021-11-12 | $1.47M 10-Q · filed 2020-11-09 | $2.79M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $322.00K 10-Q · filed 2021-08-12 | $316.00K 10-Q · filed 2020-08-07 | $802.00K 10-Q · filed 2021-08-12 | $761.00K 10-Q · filed 2020-08-07 | $2.07M derived: sum of 3 quarters · filed 2022-03-01 | $2.35M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $480.00K 10-Q · filed 2021-05-14 | $445.00K 10-Q · filed 2020-05-11 | $1.75M derived: sum of 2 quarters · filed 2022-03-01 | $2.03M derived: sum of 3 quarters · filed 2022-03-01 | $2.55M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.55M derived: sum of 2 quarters · filed 2022-03-01 | $2.07M derived: sum of 3 quarters · filed 2022-03-01 | $3.42M 10-K · filed 2022-03-01 | $2.63M 10-K · filed 2020-03-25 | |||
| 2019-09-30 | $277.00K 10-Q · filed 2020-11-09 | $799.00K derived: sum of 2 quarters · filed 2020-11-09 | $2.15M 10-Q · filed 2020-11-09 | $3.56M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-06-30 | $522.00K 10-Q · filed 2020-08-07 | $1.87M 10-Q · filed 2020-08-07 | $3.28M derived: sum of 3 quarters · filed 2021-03-04 | $7.25M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-03-31 | $1.35M 10-Q · filed 2020-05-11 | $2.76M derived: sum of 2 quarters · filed 2021-03-04 | $6.73M derived: sum of 3 quarters · filed 2021-03-04 | $15.66M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2018-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $5.38M derived: sum of 2 quarters · filed 2021-03-04 | $14.31M derived: sum of 3 quarters · filed 2021-03-04 | $23.38M 10-K · filed 2021-03-04 | ||||
| 2018-09-30 | $3.97M 10-Q · filed 2019-11-05 | $12.90M derived: sum of 2 quarters · filed 2019-11-05 | $21.98M 10-Q · filed 2019-11-05 | $30.86M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2018-06-30 | $8.93M 10-Q · filed 2019-08-06 | $18.01M 10-Q · filed 2019-08-06 | $26.89M derived: sum of 3 quarters · filed 2020-03-25 | $35.60M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2018-03-31 | $9.07M 10-Q · filed 2019-05-08 | $17.96M derived: sum of 2 quarters · filed 2020-03-25 | $26.67M derived: sum of 3 quarters · filed 2020-03-25 | $36.05M derived: sum of 4 quarters · filed 2020-03-25 | ||||
| 2017-12-31 | $8.88M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $17.60M derived: sum of 2 quarters · filed 2020-03-25 | $26.98M derived: sum of 3 quarters · filed 2020-03-25 | $37.00M 10-K · filed 2020-03-25 | ||||
| 2017-09-30 | $8.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $18.09M derived: sum of 2 quarters · filed 2017-11-07 | $28.11M 10-Q · filed 2017-11-07 | $39.38M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2017-06-30 | $9.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $19.40M 10-Q · filed 2017-08-07 | $30.66M derived: sum of 3 quarters · filed 2019-03-13 | $49.33M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2017-03-31 | $10.02M 10-Q · filed 2017-05-08 | $21.28M derived: sum of 2 quarters · filed 2019-03-13 | $39.95M derived: sum of 3 quarters · filed 2019-03-13 | $63.34M derived: sum of 4 quarters · filed 2019-03-13 | ||||
| 2016-12-31 | $11.27M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $29.93M derived: sum of 2 quarters · filed 2019-03-13 | $53.32M derived: sum of 3 quarters · filed 2019-03-13 | $73.85M 10-K · filed 2019-03-13 | ||||
| 2016-09-30 | $18.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $42.05M derived: sum of 2 quarters · filed 2016-11-10 | $62.59M 10-Q · filed 2016-11-10 | $133.14M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-06-30 | $23.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $43.92M 10-Q · filed 2016-08-15 | $114.47M derived: sum of 3 quarters · filed 2018-03-12 | $150.57M derived: sum of 4 quarters · filed 2018-03-12 | ||||
| 2016-03-31 | $20.54M 10-Q · filed 2016-05-16 | $91.09M derived: sum of 2 quarters · filed 2018-03-12 | $127.19M derived: sum of 3 quarters · filed 2018-03-12 | |||||
| 2015-12-31 | $70.55M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $106.66M derived: sum of 2 quarters · filed 2018-03-12 | $211.22M 10-K · filed 2018-03-12 | |||||
| 2015-09-30 | $36.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $140.67M 10-Q · filed 2015-11-12 | ||||||
| 2015-06-30 | $104.56M 10-Q · filed 2015-09-10 | |||||||
| 2014-12-31 | $562.00K 10-K · filed 2017-03-15 | |||||||
| 2013-12-31 | $884.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |